Literature DB >> 19746768

Standard management options for rosacea, part 2: options according to subtype.

Richard Odom1, Mark Dahl, Jeffrey Dover, Zoe Draelos, Lynn Drake, Marian Macsai, Frank Powell, Diane Thiboutot, Guy F Webster, Jonathan Wilkin.   

Abstract

The standard management options were developed by a consensus committee and review panel of 26 experts to assist in providing optimal patient care based on the standard classification and grading systems for rosacea that were developed to perform research; analyze results and compare data from different sources; and provide a common terminology and reference for the diagnosis, treatment, and assessment of results in clinical practice. We discuss the standard management options for rosacea in 2 parts: (1) overview and broad spectrum of care, and (2) management options according to subtype. The menu of options is considered provisional and may be expanded and updated as appropriate. Managing the various potential signs and symptoms of rosacea calls for consideration of a broad spectrum of care, and a more precise selection of therapeutic options may become increasingly possible as the mechanisms of action of therapies are more definitively established.

Entities:  

Mesh:

Year:  2009        PMID: 19746768

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  11 in total

Review 1.  Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit.

Authors:  Aimee M Two; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

2.  Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.

Authors:  J Fowler; M Jarratt; A Moore; K Meadows; A Pollack; M Steinhoff; Y Liu; M Leoni
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

Review 3.  A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Authors:  Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

4.  Treatment Outcomes of Long-Pulsed Nd: YAG Laser for Two Different Subtypes of Rosacea.

Authors:  Ekin Mese Say; Gokhan Okan; Gonca Gökdemir
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

5.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

6.  Ocular response analyser measurements and central corneal thickness in ocular rosacea patients.

Authors:  Melis Palamar; Cumali Degirmenci; Ilgen Ertam; Ayse Yagci
Journal:  Int Ophthalmol       Date:  2016-03-12       Impact factor: 2.031

7.  Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.

Authors:  Alvin B Coda; Tissa Hata; Jeremiah Miller; David Audish; Paul Kotol; Aimee Two; Faiza Shafiq; Kenshi Yamasaki; Julie C Harper; James Q Del Rosso; Richard L Gallo
Journal:  J Am Acad Dermatol       Date:  2013-07-18       Impact factor: 11.527

8.  Preliminary open-label clinical evaluation of the soothing and reepithelialization properties of a novel topical formulation for rosacea.

Authors:  Adele Sparavigna; Beatrice Tenconi; Ileana De Ponti
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-10-24

Review 9.  Psychosocial aspects of rosacea with a focus on anxiety and depression.

Authors:  Monika Heisig; Adam Reich
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-03-06

10.  Ocular Rosacea Causing Corneal Melt in an African American Patient and a Hispanic Patient.

Authors:  Joanna S Saade; Bachir Abiad; Jonathan Jan; Dana Saadeh; James P McCulley; Jeremy Bartley
Journal:  Case Rep Ophthalmol Med       Date:  2017-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.